Interventions for treating leg ulcers in people with sickle cell disease

Martí‐Carvajal, Arturo J; Knight‐Madden, Jennifer; Martinez-Zapata, María José

doi:10.1002/14651858.cd008394.pub3

Cited by 26 publications

(24 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16 The 198 participants with 250 ulcers included in this analysis were classified into 2 groups: systemic pharmaceutical interventions and topical pharmaceutical interventions. Of all the interventions used, only RGD peptide matrix significantly reduced ulcer size compared with a control.…”

Section: Discussionmentioning

confidence: 99%

Case Studies Evaluating Transdermal Continuous Oxygen for the Treatment of Chronic Sickle Cell Ulcers

Igwegbe

Onojobi

Fadojutimi-Akinsiku

et al. 2015

Advances in Skin &Amp; Wound Care

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Case Studies Evaluating Transdermal Continuous Oxygen for the Treatment of Chronic Sickle Cell Ulcers

Igwegbe

Onojobi

Fadojutimi-Akinsiku

et al. 2015

Advances in Skin &Amp; Wound Care

View full text Add to dashboard Cite

show abstract

“…By the end of the 8-week trial, treated ulcers were 66% of the original size, a statistically significant reduction compared with the control group. However, a 2014 Cochrane Review suggests that this trial had a high risk of bias and emphasised the need for confirmatory studies (23). Much of the literature since 1987 questions the role of bacterial infections in wound pathogenesis.…”

Section: Topical Treatmentmentioning

confidence: 99%

“…The 2014 Cochrane Review found that only the 1994 trial that used an arginine-glycine-aspartic acid matrix (RGD peptide matrix) achieved noticeable benefit in the treatment of SCLUs (23,25). The RGD peptide matrix is believed to act as a synthetic extracellular matrix to promote cell migration, keratinocyte layer formation and wound strengthening.…”

Section: Topical Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease

Altman

Kleinfelder

Quigley

et al. 2015

International Wound Journal

View full text Add to dashboard Cite

Sickle cell leg ulcers (SCLUs) are a common complication of sickle cell disease (SCD). Patients who develop ulcers appear to have a more severe haemolysis-associated vasculopathy than individuals who do not develop them, and manifest other complications such as priapism and pulmonary hypertension. SCLUs are slow to heal and often recur, affecting both the emotional and physical well-being of patients. Here we summarise what is known about the pathophysiology of SCLUs, describe available treatment options and propose a treatment algorithm.

show abstract

“…There are no clinical trials of systemic antimicrobials. (Marti‐Carvajal et al , ). Topical antibiotics are often used.…”

Section: Specific Infectionsmentioning

confidence: 99%

How we prevent and manage infection in sickle cell disease

et al. 2015

View full text Add to dashboard Cite

Summary Sickle cell disease (SCD) affects approximately 100 000 people in the US, 12 500 in the UK, and millions worldwide. SCD is typified by painful vaso‐occlusive episodes, haemolytic anaemia and organ damage. A secondary complication is infection, which can be bacterial, fungal or viral. Universal newborn screening, routine use of penicillin prophylaxis, availability of conjugated vaccines against S. pneumoniae and comprehensive care programmes instituted during the past few decades in industrialized countries have dramatically reduced childhood mortality and improved life expectancy. Yet patients with SCD remain at increased risk of infection. Unfortunately, the treatment of most bacterial infections that are common in SCD is not based on the results of randomized controlled clinical trials. In their absence, treatment decisions are based on consensus guidelines, clinical experience or adapting treatment applied in other diseases. This leads to wide variation in treatment among institutions and even between treating physicians in a single institution. Prevention of infection, when possible, is most important and we focus on prevention through targeted prophylaxis and vaccination. We will share our management strategies for managing the more common infections in SCD and provide the rationale for our recommendations.

show abstract

Interventions for treating leg ulcers in people with sickle cell disease

Abstract: Editorial group: Cochrane Cystic Fibrosis and Genetic Disorders Group. Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 12, 2014.

Cited by 26 publications

References 106 publications

Case Studies Evaluating Transdermal Continuous Oxygen for the Treatment of Chronic Sickle Cell Ulcers

Case Studies Evaluating Transdermal Continuous Oxygen for the Treatment of Chronic Sickle Cell Ulcers

A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease

How we prevent and manage infection in sickle cell disease

Contact Info

Product

Resources

About